Changes in Beneficial Ownership · 4
Taysha Gene Therapies, Inc.
TSHANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-07102026_100732.xml
Filing details
- Report period
- 2026-07-10
- Issuer
- Taysha Gene Therapies, Inc.
- Issuer CIK
- 0001806310
- Trading symbol
- TSHA
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Nagendran Sukumar
- Reporting owner CIK
- 0001665124
- Relationship
- Director · Officer
- Officer title
- President and Head of R&D
- Address
- C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-07-10 | S · Form 4[F1] | 200,000 | D | 6.24[F2] | 936,410 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.↩ 1
- F2
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
Signature 1
- Signed
- /s/ Kamran Alam, Attorney-in-Fact
- Date
- 2026-07-10
Company context
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.